The drug, datopotamab deruxtecan, which is being jointly developed with Japan's Daiichi Sankyo, was shown to prolong progression-free survival compared with standard chemotherapy in patients whose non-small cell lung cancer had returned after one or two prior treatment attempts.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/lcEvAVm
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» AstraZeneca shares drop as lung cancer trial update lags expectations
https://ift.tt/SygoNmq
No comments:
Post a Comment